A selective audit: 29 claims. Links within each card lead to the topic pages.
29 / 29
No matches. Reset the filters.
DXM and DXO are both pharmacologically active
This point remains valid. Modern evidence clarifies differences between their targets and the contribution of metabolism to effects.
Retained
According to the 2026 audit · edition
Evidence and limitations
What was examined: Studies altering CYP2D6 activity show that shifts in the balance of DXM and DXO change the profile of subjective responses. Xiao’s paper compares target binding in vitro.
Limits of the conclusion: Each substance’s contribution depends on exposure and the study endpoint. Binding data concern the biological system studied; their relevance to effects in humans remains uncertain.
The main pathway is described correctly. Conversion rates vary with genetic variants of the enzyme and drug inhibition.
Retained
According to the 2026 audit · edition
Evidence and limitations
What was examined: Capon’s pharmacokinetic study and Rüdesheim’s model link CYP2D6 activity to DXM exposure. Zawertailo’s studies also examine subjective effects.
Limits of the conclusion: Interpretation depends on formulation, concomitant medicines and the measure being examined.
With reduced CYP2D6 activity, DXM exposure can increase substantially. The experience also changes: a small study reported greater sedation, dysphoria and psychomotor impairment.
Corrected
According to the 2026 audit · edition
Evidence and limitations
What was examined: Capon examined pharmacokinetics in poor and extensive metabolizers; Zawertailo’s pilot study compared their subjective and psychomotor responses.
Limits of the conclusion: The finding applies to the conditions of these small studies. Genotype accounts for part of the variability, while individual responses also depend on other factors.
Modern terminology distinguishes PM, IM, NM and UM: poor, intermediate, normal and ultrarapid metabolism. Functional activity of variants and the effects of medicines on actual enzyme activity are considered.
Clarified
According to the 2026 audit · edition
Evidence and limitations
What was examined: Caudle’s consensus standardizes translation of CYP2D6 genotype into phenotype; Rüdesheim’s model applies modern categories to DXM pharmacokinetics.
Limits of the conclusion: The historical label EM requires checking the definition used in the particular study. Enzyme inhibitors can alter the functional phenotype, a process called phenoconversion.
A modern scheme also includes DXO glucuronidation. Results should distinguish unconjugated DXO, total DXO and the protein-unbound fraction.
Clarified
According to the 2026 audit · edition
Evidence and limitations
What was examined: Lutz’s paper examines how CYP-dependent and subsequent pathways affect assessment of metabolism; Rüdesheim’s model accounts for processing of DXM and DXO.
Limits of the conclusion: The meaning of a measurement depends on the analytical method. Concentrations can be compared after identifying which form of the substance was measured.
PCP2 is an older label for binding sites. Its association with DAT and its use to explain the first plateau remain hypotheses.
Remains a hypothesis
According to the 2026 audit · edition
Evidence and limitations
What was examined: Meoni studied dextromethorphan binding sites in rat brain and obtained evidence linking part of the observations to serotonin transport. Xiao’s modern paper examines several known targets.
Limits of the conclusion: Establishing a molecular target requires independent evidence on the identity of the site and the function of the protein.
DM2 findings are better described through the conditions of the particular experiment. Some older observations are consistent with sites associated with serotonin transport.
Clarified
According to the 2026 audit · edition
Evidence and limitations
What was examined: In Meoni’s rat-brain study, binding was sodium-dependent; distribution and mutual displacement with paroxetine supported an association with the serotonin uptake system.
Limits of the conclusion: The older labels grouped different experimental observations. Each site requires its own molecular identification.
The structure of sigma-1 was later published, and sigma-2 was identified as TMEM97. These discoveries update the older description.
Clarified
According to the 2026 audit · edition
Evidence and limitations
What was examined: Schmidt presented the crystal structure of human sigma-1. Alon showed that TMEM97 corresponds to sigma-2.
Limits of the conclusion: Molecular descriptions help investigate receptor functions. Receptor function and a particular subjective effect belong to different levels of description.
Sigma receptors and unusual sensations of movement
This explanation remains a hypothesis. Sigma-1 findings in experimental models and prescription labeling concern other endpoints.
Remains a hypothesis
According to the 2026 audit · edition
Evidence and limitations
What was examined: Nguyen examined antidepressant-like effects of DXM in a mouse model. The Auvelity label describes DXM’s pharmacological targets and notes uncertainty about the mechanism of therapeutic action.
Limits of the conclusion: A mouse behavioral model and human subjective experiences require different methods of evaluation.
In the audit, this remains an unconfirmed historical hypothesis. It offers a weak basis for explaining modern DXM findings.
Remains a hypothesis
According to the 2026 audit · edition
Evidence and limitations
What was examined: For this row, the audit cites the FAQ itself. Its bibliography contains no separate modern primary confirmation.
Limits of the conclusion: This describes the sources in the audit’s bibliography; a comprehensive literature search on the hypothesis lies outside its scope.
The main association remains valid. DXM and DXO differ in binding profiles, while each target’s precise contribution to human effects remains a research question.
Retained
According to the 2026 audit · edition
Evidence and limitations
What was examined: Carbonaro’s and Shram’s papers describe controlled studies of DXM effects in humans. Xiao provides in-vitro binding data; the Auvelity label includes NMDA in its pharmacology description.
Limits of the conclusion: Plasma concentration, laboratory affinity and receptor occupancy in the brain are different measures. Relating them requires an appropriate model and data.
These categories help describe reports of experience. Their boundaries vary with metabolism, formulation, combinations and individual characteristics.
Clarified
According to the 2026 audit · edition
Evidence and limitations
What was examined: CYP2D6 studies and changes in the DXM/DXO balance show qualitative variability in responses. This calls for caution when applying the historical classification to an individual.
Limits of the conclusion: Clinical conclusions require measured exposures and endpoints. A plateau description remains a subjective category.
The scheme is best retained as a historical model. DXM and DXO concentrations, binding and functional effects describe different aspects of the substances’ actions.
Remains a hypothesis
According to the 2026 audit · edition
Evidence and limitations
What was examined: Xiao compares DXM and DXO targets in vitro. These measurements differ from receptor-occupancy data in the living brain.
Limits of the conclusion: The original scheme was a qualitative proposal. This audit provides no established thresholds for sequential target activation across plateaus.
Historical paraphrase · FAQ 4.0 · 1997 · §9.3.1 White proposed a qualitative sequence of target involvement, including PCP2, and qualified it as approximate.
A controlled study now includes a direct comparison with DXM. It examined abuse potential and subjective effects under specific conditions.
Clarified
According to the 2026 audit · edition
Evidence and limitations
What was examined: In Shram’s paper, the principal comparison concerned ketamine and placebo; DXM served as an additional exploratory comparator.
Limits of the conclusion: The results apply to the selected participants, administration routes and measures. Comparing all forms and varieties of dissociative experience remains a broader task.
Serotonin toxicity involving DXM is described in clinical publications. It should be presented as a documented complication, particularly in combinations with serotonergic agents.
Corrected
According to the 2026 audit · edition
Evidence and limitations
What was examined: Monte reviews overdose cases involving products with DXM and chlorpheniramine. Harada describes a fatal case involving overdose of DXM and moclobemide. The Auvelity label also carries a warning.
Limits of the conclusion: Clinical cases establish that the complication can occur; its frequency across all doses and combinations is difficult to determine from them.
Historical paraphrase · FAQ 4.0 · 1997 · §6.2.9 The FAQ places serotonin syndrome under a theoretical heading, although its text already discusses hazardous combinations.
The warning remains applicable and deserves prominent presentation. Modern clinical reports and prescription labeling add to the historical basis.
Retained
According to the 2026 audit · edition
Evidence and limitations
What was examined: Harada describes a fatal case involving moclobemide. The Auvelity label contraindicates combination with MAO inhibitors and includes specific provisions for linezolid and intravenous methylene blue.
Limits of the conclusion: Specific medicine restrictions are checked against the current label for the product concerned. This section examines the historical text.
It is important to distinguish changes in DXM exposure from the combination’s serotonergic effects. Both pathways matter for fluoxetine and paroxetine.
Clarified
According to the 2026 audit · edition
Evidence and limitations
What was examined: Chyka’s clinical guideline accounts for interacting medicines; the Auvelity label includes a serotonin-syndrome warning and information about CYP2D6 inhibition.
Limits of the conclusion: The pathways can coexist. Their contribution depends on the particular medicine, regimen and other ingredients.
That broad judgment should be removed. Diphenhydramine’s own sedative and antimuscarinic effects matter, as does its inhibition of CYP2D6.
Corrected
According to the 2026 audit · edition
Evidence and limitations
What was examined: Hamelin demonstrated effects of diphenhydramine on CYP2D6-dependent metoprolol metabolism in humans. Chyka’s guideline calls for considering accompanying ingredients in DXM poisoning.
Limits of the conclusion: Hamelin’s study used metoprolol. Quantifying the interaction directly with DXM requires its own data.
The characteristic diagnostic clue in the reported case is falsely high chloride and a low or negative anion gap. Bromide interference with chloride measurement explains it.
Corrected
According to the 2026 audit · edition
Evidence and limitations
What was examined: Ng describes chronic use of syrup containing DXM hydrobromide and acetaminophen, pseudohyperchloremia and a negative anion gap.
Limits of the conclusion: The laboratory effect depends on the measurement method. Interpretation requires the product’s ingredients and clinical context.
Clinical guidance allows consideration of naloxone in marked sedation or coma, particularly with respiratory depression. The overall response in DXM intoxication remains unpredictable.
Corrected
According to the 2026 audit · edition
Evidence and limitations
What was examined: Chyka’s consensus guideline assigns this recommendation Grade C. It addresses poisoning management and patient referral.
Limits of the conclusion: Use belongs within medical care. This section explains the evidence without providing a self-treatment protocol.
Animal experiments, human MRI associations and claims of specific neuronal damage require separate interpretation. In 2004, White withdrew claims from his 1998 neurotoxicity text.
Clarified
According to the 2026 audit · edition
Evidence and limitations
What was examined: Carliss and Tran examined different administration routes and endpoints in rats. Qiu compared MRI findings in people dependent on DXM and a control group. White’s response records withdrawal of his earlier conclusions.
Limits of the conclusion: Transferring animal pathology to humans requires evidence. MRI associations allow several explanations; Olney lesions in humans after DXM have not been established in the reviewed sources.
Historical paraphrase · FAQ 4.0 · 1997 · §6.3.1 The FAQ discusses reports of lasting impairment and their resemblance to descriptions of Olney lesions. White later strengthened these claims in a separate text.
A modern description should name the formulation explicitly. DXM hydrobromide and polistirex have different profiles; absorption timing depends on the product and conditions.
Clarified
According to the 2026 audit · edition
Evidence and limitations
What was examined: The Delsym label describes an extended-release polistirex suspension. The Auvelity label distinguishes immediate-release DXM from extended-release bupropion.
Limits of the conclusion: Read the active-ingredient amount on the label together with the stated salt and formulation. Assessing bromide requires the actual product composition.
Assessment should use the complete ingredient list. Antihistamines, acetaminophen and other components have their own risks, which depend on the substance and exposure.
Clarified
According to the 2026 audit · edition
Evidence and limitations
What was examined: Monte examines serotonin toxicity in overdose involving DXM and chlorpheniramine. Chyka’s guideline separately requires consideration of accompanying product ingredients.
Limits of the conclusion: A subjective plateau category offers little help in assessing toxicity of additional ingredients. Their names and amounts are needed.
The modern picture includes a prescription combination of DXM and bupropion: Auvelity has a US indication for major depressive disorder in adults. In 2026, the FDA added agitation associated with dementia due to Alzheimer’s disease.
Corrected
According to the 2026 audit · edition
Evidence and limitations
What was examined: The current label describes a specific combination product and clinical studies supporting its indications. Bupropion increases DXM exposure through CYP2D6 inhibition.
Limits of the conclusion: The conclusion concerns the product composition and indications studied. The label describes DXM’s therapeutic mechanism as unclear.